Antisense oligonucleotides are synthetic strings of nucleic acid, which reduce expression of messenger RNA (m-RNA). The function performed by interference with pre m- RNA splicing are restoration of protein and modification of protein. Antisense oligonucleotide is a new approach to treat several neurodegenerative disorders to prevent disease onset or stop disease development.
Market Dynamics
Increasing prevalence of neurodegenerative disease is a major factor driving CNS specific antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020.
Key features of the study:
- This report provides in-depth analysis of the CNS specific antisense oligonucleotide market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the global CNS specific antisense oligonucleotide market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., Q-STATE BIOSCIENCES, INC.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global CNS specific antisense oligonucleotide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the CNS specific antisense oligonucleotide market
Detailed Segmentation:
- Global CNS Specific Antisense Oligonucleotide Market, By Drug:
- Approved
- Patisiran
- Nusinersen
- Inotersen
- Pipeline
- Global CNS Specific Antisense Oligonucleotide Market, By Indication:
- Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
- Spinal Muscular Atrophy
- Huntington’s Disease
- Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global CNS Specific Antisense Oligonucleotide Market, By Geography:
- North America
- By Drug:
- Approved
- Patisiran
- Nusinersen
- Inotersen
- Pipeline
- By Indication:
- Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
- Spinal Muscular Atrophy
- Huntington’s Disease
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country:
- Latin America
- By Drug:
- Approved
- Patisiran
- Nusinersen
- Inotersen
- Pipeline
- By Indication:
- Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
- Spinal Muscular Atrophy
- Huntington’s Disease
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug:
- Approved
- Patisiran
- Nusinersen
- Inotersen
- Pipeline
- By Indication:
- Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
- Spinal Muscular Atrophy
- Huntington’s Disease
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug:
- Approved
- Patisiran
- Nusinersen
- Inotersen
- Pipeline
- By Indication:
- Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
- Spinal Muscular Atrophy
- Huntington’s Disease
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug:
- Approved
- Patisiran
- Nusinersen
- Inotersen
- Pipeline
- By Indication:
- Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
- Spinal Muscular Atrophy
- Huntington’s Disease
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug:
- Approved
- Patisiran
- Nusinersen
- Inotersen
- Pipeline
- By Indication:
- Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
- Spinal Muscular Atrophy
- Huntington’s Disease
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Alnylam Pharmaceuticals Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Sarepta Therapeutics Inc.
- Biogen Inc.
- Ionis Pharmaceuticals Inc.
- Wave Life Sciences Ltd.
- Stroke Therapeutic Inc.
- Dynacure
- ProQR Therapeutics N.V.
- Q-STATE BIOSCIENCES, INC.
“*” marked represents similar segmentation in other categories in the respective section.
